AML

>

Latest News

FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML
FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML

October 17th 2024

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.

FDA Clears IND of Novel ADC in AML Treatment
FDA Clears IND of Novel ADC in AML Treatment

October 14th 2024

Targeting AML: The Latest Advances
Targeting AML: The Latest Advances

September 20th 2024

SELECT-AML-1 Trial of Tamibarotene Combo in AML Discontinues Enrollment
SELECT-AML-1 Trial of Tamibarotene Combo in AML Discontinues Enrollment

August 13th 2024

FDA Grants Rare Pediatric Disease Designation to SLS009 in Pediatric AML
FDA Grants Rare Pediatric Disease Designation to SLS009 in Pediatric AML

July 16th 2024